IP Library › Granted Patent US 9,867,839
Granted Patent B2
US 9,867,839 · App. 15/438,513 · Granted Jan 16, 2018

Osteoclast inhibitors for joint conditions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,867,839
App. No.
15/438,513
Granted
Jan 16, 2018
Kind
B2
Abstract

Oral dosage forms of osteoclast inhibitors, such as neridronic acid and zoledronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as joint conditions.

Claims (30)

1. A method of treating pain associated with a joint comprising: administering neridronic acid in an acid form or a salt form to a patient who has suffered for at least 3 months with 1) pain associated with a joint and 2) a pain intensity of 5 or greater measured using the 0-10 numerical rating scale (NRS) or 5 cm or greater using the 10 cm visual analog scale (VAS).

2. The method of claim 1 , wherein the patient has a pain intensity of 8 or greater measured using the 0-10 NRS or 8 cm or greater using the 10 cm VAS.

3. The method of claim 1 , wherein the patient has a pain intensity of 9 or greater measured using the 0-10 NRS or 9 cm or greater using the 10 cm VAS.

4. The method of claim 1 , wherein the neridronic acid is administered parenterally.

5. The method of claim 4 , wherein the neridronic acid is administered at an interval of 2, 3, or 4 days.

6. The method of claim 1 , wherein the joint is a knee.

7. The method of claim 1 , wherein the joint is an elbow.

8. The method of claim 1 , wherein the joint is a wrist.

9. The method of claim 1 , wherein the joint is an ankle.

10. The method of claim 1 , wherein the patient is suffering from complex regional pain syndrome.

11. The method of claim 2 , wherein the patient is suffering from complex regional pain syndrome.

12. The method of claim 3 , wherein the patient is suffering from complex regional pain syndrome.

13. The method of claim 1 , wherein the neridronic acid is administered parenterally at an interval of 2, 3, or 4 days, and the patient has a pain intensity of 7 or greater measured using the 0-10 NRS or 7 cm or greater using the 10 cm VAS.

14. The method of claim 13 wherein each parenteral dose is about 10 mg to about 150 mg.

15. A method of treating pain associated with a joint comprising: orally administering zoledronic acid in an acid form or a salt form to a patient having 1) pain associated with a joint and 2) a pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS, wherein a total of about 400 mg to about 600 mg of zoledronic acid is administered in 2 or 3 individual doses within a period of about a month.

16. The method of claim 15 , wherein the patient has a pain intensity of 6 or greater measured using the 0-10 NRS or 6 cm or greater using the 10 cm VAS.

17. The method of claim 15 , wherein the patient has a pain intensity of 7 or greater measured using the 0-10 NRS or 7 cm or greater using the 10 cm VAS.

18. The method of claim 15 , wherein the patient has a pain intensity of 8 or greater measured using the 0-10 NRS or 8 cm or greater using the 10 cm VAS.

19. The method of claim 15 , wherein the patient has a pain intensity of 9 or greater measured using the 0-10 NRS or 9 cm or greater using the 10 cm VAS.

20. The method of claim 15 , wherein the joint is a knee.

21. The method of claim 15 , wherein the joint is an elbow.

22. The method of claim 15 , wherein the joint is a wrist.

23. The method of claim 15 , wherein the joint is an ankle.

24. The method of claim 15 , wherein the patient is suffering from complex regional pain syndrome.

25. The method of claim 15 , wherein the zoledronic acid is in a salt form.

26. The method of claim 15 , wherein the zoledronic acid is in the form of a molecular complex with an amino acid.

27. The method of claim 26 , wherein the amino acid is lysine.

28. The method of claim 27 , wherein the molecualr complex is administered in 3 individual doses, and wherein each of the 3 individual doses contain about 160 mg of the zoledronic acid.

29. The method of claim 16 , wherein the zoledronic acid is in the form of a molecular complex with an amino acid.

30. The method of claim 29 , wherein the molecular complex is administered in 3 individual doses, and wherein each of the 3 individual doses contain about 160 mg of the zoledronic acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2017
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 041570/0113 →